True North Therapeutics Secures $40,000,000 Series C Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d796d2b8-1eb5-4c4e-a308-2d44405a2eba - Date
12/3/2015 - Company Name
True North Therapeutics - Mailing Address
951 Gateway Blvd. South San Francisco, CA 94080 USA - Company Description
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. - Website
http://www.truenorthrx.com - Transaction Type
Venture Equity - Transaction Amount
$40,000,000 - Transaction Round
Series C - Proceeds Purposes
Proceeds from the financing will be used to advance the clinical development of its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases targeting the Complement system. - M&A Terms
- Venture Investor
New Leaf Venture Partners - Venture Investor
Perceptive Advisors - Venture Investor
Cowen Capital Partners - Venture Investor
Kleiner Perkins Caufield & Byers - Venture Investor
MPM Capital - Venture Investor
OrbiMed - Venture Investor
SR One - Venture Investor
Baxalta Ventures
